Global Oncology Biosimilars Market Was Valued at USD 3.5 Billion in 2021, growing Pipeline Assets Driving the market

According to Precision Business Insights (PBI), the latest report, the oncology biosimilars market is expected to be worth USD 4.5 billion in 2022, growing at a 30.0% CAGR from 2022 to 2028. The global oncology biosimilars market is segmented into the following types: By Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF,…

According to Precision Business Insights (PBI), the latest report, the oncology biosimilars market is expected to be worth USD 4.5 billion in 2022, growing at a 30.0% CAGR from 2022 to 2028. The global oncology biosimilars market is segmented into the following types: By Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others), By Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, and Others), and Geography (North America, Europe, Asia Pacific, Latin America, and MEA). Key players’ profiles in the Oncology Biosimilars market report are Biocoin, Celltrion inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer inc., Apotex inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, and Hospira. The manufacture of new oncology biosimilars is driven by the patent expiration of biologics used to treat cancer. These cancer-targeting medications are made from living organisms that trigger the immune system to attack cancer cells. Biosimilars are similar to biologics but not identical to them, and they provide the same efficacy as biologics at a lower cost. According to the Center for Biosimilars, patents on roughly 20 oncology biologics will expire by 2023, an opening framework for the growth of the development of new biosimilars in cancer therapy. The growing frequency of patent expirations is likely to raise demand for new oncology biosimilars, propelling the market for oncology biosimilars forward.

Blood  Cancer  Segment  to  Dominate  the  Oncology  Biosimilars  Market:

The blood cancer segment is expected to account for a larger revenue share in the global oncology biosimilars market. Blood cancer is a life-threatening malignancy that affects the production or function of blood cells such as bone marrow and tissues, resulting in lymphatic system failure. The increase in the number of new treatments in the pipelines of major pharmaceutical companies will drive the market. More than one-fifth of the oncology biosimilars market is predicted to come from blood cancers. Increased awareness among healthcare professionals and patients about the prospect of early cancer diagnosis is driving market expansion. Increased government funding for research is expected to accelerate market growth throughout the projected period.

Europe Oncology Biosimilars Market:

The Europe market is expected to hold a significant market share in the global oncology biosimilars market over the forecast period. It is projected to grow at a CAGR of 32.0% in the coming years. The European market is likely to expand rapidly. This is because significant biosimilars are projected to be launched throughout the forecast period. Leading generic manufacturers in Europe, such as Sandoz (a branch of Novartis International AG) and Mylan N.V., have expressed interest in this subject. In 2017, the duo received FDA approval for their first biosimilar product. Also, in the same year, a resubmission for their Herceptin biosimilar was accepted by the European Medicines Agency (EMA). The oncology biosimilars market in the region is predicted to increase significantly over the forecast period due to an increasing number of biosimilars approvals.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:

The global oncology biosimilars market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance,

  • In February 2021, Coherus and Junshi Biosciences announced a collaboration where Coherus would in-license toripalimab, an anti-PD-1 antibody, in the US and Canada.

Request sample report at  https://precisionbusinessinsights.com/request-sample?product_id=19301                                        

The oncology biosimilars market detailed segmentation:

Based  on  the  drug  type:

  • Monoclonal Antibody
  • Immunomodulators
  • G-CSF
  • Hematopoietic Agents
  • Others

Based on the cancer type:

  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Breast Cancer
  • Others

Based on  the  geography:

  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact US:
Mr. Satya
Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX